Both the 4-week cohort (pre-symptomatic) and 8-week (symptomatic) anti-SEMA4D antibody-treated Rett syndrome cohorts showed significant improvements in the phenotypic clinical scores relative to the isotype control antibody groups. This evidence concerns the gene SEMA4D and atypical Rett syndrome.